Citation(s)
- S Kent, M Boyce, Z Diamont, D Singh, B O'Connor, P Saggu, V Norris
The 5-lipoxygenase activating protein inhibitor, GSK2190915, attenuates allergen induced asthmatic response in subjects with mild asthma: a randomized, double-blind, placebo controlled two-period cross over study. Clin Exp Allergy. 2013;43:177-186.
A Randomised, Double-blind, Placebo-controlled, 2-period Cross-over Study to Evaluate the Effect of Treatment With GSK2190915 on the Allergen-induced Asthmatic Response in Subjects With Mild Asthma
Details for clinical trial NCT00748306